Experimental Alzheimer’s Drug Testing Ended

Eli Lilly, the giant pharmaceutical company, has decided to halt the development of its latest experimental drug which was a hopeful candidate for treating Alzheimer’s disease. Instead of helping sufferers of this illness, which causes severe memory loss and dementia in mostly older people, the drug was actually thought to be worsening the condition upon administration.

The medication, semagacestat was showed in preliminary results from large studies that cognition and the performance of daily tasks was hindered markedly due to the drug. There was also data from the studies that showed an association of use of the drug with an increased risk of skin cancer.

Although the loss of this drug from the future in the  fight against Alzheimer’s is a disappointment, Eli Lilly reassured those concerned that this decision in no way alters the continuing development and testing of solanzumab, another drug with hopeful possibilities for a future treatment for Alzheimer’s disease.

About

Rachel Forsythe has a B.A. in English Literature and worked as an editor for a local weekly news magazine. She is now a stay-at-home mom, raising three younger boys and two older daughters. Her favorite activities are hiking, reading, traveling, bike riding, skiing in the winter and surfing in the summer. She also loves to cook. Be in touch with Rachel at Rachel[at]sunstoneonline.com

View all posts by